

1           Menopausal vasomotor symptoms and  
2           subclinical atherosclerotic cardiovascular  
3           disease – a population-based study  
4           Short title: Vasomotor symptoms and  
5           subclinical atherosclerosis  
6

7   Sigrid Nilsson MD PhD Student<sup>1\*</sup>, Angelika Qvick MD PhD student<sup>2</sup>, Moa Henriksson  
8   Medical student PhD student<sup>1</sup>, Sofia Sederholm Lawesson MD PhD<sup>3</sup>, Anna-Clara Spetz Holm  
9   MD PhD<sup>1</sup>, Karin Leander MPH PhD<sup>2</sup>.

10   <sup>1</sup> Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and  
11   Clinical Sciences, Linköping University, Linköping, Sweden.

12   <sup>2</sup> Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine,  
13   Karolinska Institutet, Stockholm, Sweden.

14   <sup>3</sup> Department of Cardiology, and Department of Health, Medicine and Caring Sciences,  
15   Linköping University, Linköping, Sweden.

16

17   **\*Corresponding author:**

18   Sigrid Nilsson

19   Department of Obstetrics and Gynecology in Linköping, and Department of Biomedical and  
20   Clinical Sciences, Linköping University, Linköping

21   58185 Linköping, Sweden.

22   E-mail: [sigrid.nilsson@liu.se](mailto:sigrid.nilsson@liu.se)

23   Telephone number: +46761107007

24   **Total word count: 4962**

25

## 26 ABSTRACT

### 27 BACKGROUND

28 Menopausal vasomotor symptoms (VMS) have been associated with subclinical and manifest  
29 atherosclerotic cardiovascular disease (ASCVD) but have not been studied in relation to  
30 image-detected coronary atherosclerosis. We assessed the association between VMS and  
31 subclinical ASCVD in peri- and postmenopausal women, considering a wide range of  
32 cardiovascular related risk factors that could potentially influence the relationship.

### 33 METHODS

34 This cross-sectional population-based study was conducted on a subset of participants from  
35 the Swedish CARDioPulmonary BioImage Study (SCAPIS), including women 50-65 years of  
36 age. The women underwent comprehensive cardiovascular assessments and completed an  
37 extensive questionnaire, which included questions about current and previous menopause-  
38 related symptoms. VMS was assessed on a 4-point scale and analyzed in relation to  
39 subclinical ASCVD, detected via coronary computed tomography angiography (CCTA),  
40 coronary artery calcium score (CACs) and carotid ultrasound using logistic regression  
41 analyses.

### 42 RESULTS

43 Of 2995 women included, 14.2% reported previous or on-going severe VMS (n=425), 18.1%  
44 moderate VMS (n=543), and 67.7% no or mild VMS (n=2027). Women who had ever  
45 experienced severe VMS, but not those with ever moderate VMS, had higher prevalence of  
46 CCTA-detected coronary atherosclerosis (34.1 vs 27.8%, p=0.017), but not segmental  
47 involvement score (SIS) >3 (4.5 vs 5.1%, p=0.332), CACS>100 (5.8 vs 6.8%, p=0.166) or  
48 any carotid plaque (47.6% vs 46.6%, p=249) than women with never or ever mild VMS.  
49 Using the same reference, ever severe but not moderate VMS was significantly associated  
50 with CCTA-detected coronary atherosclerosis, odds ratio (OR) after multivariable adjustment  
51 1.33, 95% CI 1.02–1.72. This association was only present for durations of severe VMS of  
52 more than 5 years (multivariable adjusted OR 1.53 95% CI 1.09-2.14) or when the onset of  
53 severe VMS occurred before menopause (multivariable adjusted OR 1.60 95% CI 1.06-2.42).  
54 Additional adjustment for menopausal hormone therapy strengthened the associations  
55 whereas additional adjustment for physical activity did not. No significant association with  
56 SIS>3, CACS>100, nor with any carotid plaque was observed.

57 **CONCLUSIONS**

58 Previous or on-going severe but not moderate VMS were significantly associated with CCTA-  
59 detected coronary atherosclerosis, independent of a broad range of cardiovascular risk factors.

60 No corresponding associations was observed for SIS>3, CACS>100 or carotid  
61 atherosclerosis.

62

63

64 **KEY WORDS:**

65 Vasomotor symptoms; Menopause; Menopausal symptoms; Subclinical  
66 atherosclerosis; Cardiovascular disease.

67

## 68 Abbreviations

69 ASCVD – atherosclerotic cardiovascular disease

70 CAC – coronary artery calcium

71 CACS – coronary artery calcium score

72 CCTA – coronary computed tomography angiography

73 C-IMT – carotid intima media thickness

74 CT – computed tomography

75 CVD – cardiovascular disease

76 MHT – menopausal hormone therapy

77 MVPA – moderate to vigorous physical activity

78 SCAPIS – Swedish CArdioPulmonary bioImage Study

79 SIS – segment involvement score

80 SWH – Study of Women’s health

81 VMS – vasomotor symptoms

82 **Clinical Perspective:**

83 • What is new?

84 ○ Previous or ongoing severe vasomotor symptoms were, independent of a wide  
85 range of cardiovascular risk factors, significantly associated with coronary  
86 atherosclerosis identified by coronary computed tomography angiography  
87 screening of the general population, aged 50-65 years.

88 ○ The association was limited to women with a duration of severe vasomotor  
89 symptoms of more than five years or whose severe vasomotor symptoms began  
90 before menopause onset.

91 • What are the clinical implications?

92 ○ Our results reflect a need for extra vigilance regarding cardiovascular risk factors  
93 in women suffering from severe vasomotor symptoms.

## 94 1. Introduction

95 Atherosclerotic cardiovascular disease (ASCVD) is a major cause of mortality and morbidity  
96 in women (1), to which female reproductive factors appear to contribute (2, 3). To improve  
97 primary prevention strategies for ASCVD in women, there is a need for greater understanding  
98 of female specific risk factors that can be the focus of targeted preventive efforts (4).

99 Susceptibility to ASCVD in women increases considerably after menopause (5, 6), when  
100 estrogen levels decline sharply (7) and the prevalence of cardiovascular risk factors increases  
101 (8, 9). The decline in estrogen levels is often accompanied by climacteric symptoms (7), such  
102 as hot flushes and night sweats, known as vasomotor symptoms (VMS), affecting  
103 approximately 80-97% of women (10, 11) with varying frequency and severity (10, 12). The  
104 VMS duration is usually between 5 and 7 years (11, 13), but with an early onset the duration  
105 appears to be longer (10). There is an association between VMS and sleep-related problems,  
106 depressive symptoms, and a generally impaired quality of life (13, 14), especially among  
107 women with long VMS duration (13).

108 The most effective VMS treatment is menopausal hormone therapy (MHT) with either  
109 estrogen alone or in combination with gestagen. The prescription rate, however, has been  
110 relatively low for the past two decades, mainly due to cardiovascular safety concerns (15).  
111 Whereas endogenous estrogen appears to counteract the early atherosclerosis process (16), the  
112 menopausal transition is linked to progressive changes in tissue estrogen receptor  
113 characteristic (17). Consequently, the response to exogenously administered estrogen may  
114 differ depending on when treatment is initiated (18). Current guidelines support MHT for  
115 bothersome VMS in women within 10 years since menopause or  $\leq 60$  years of age at treatment  
116 initiation (19). Another proposed therapy for treatment of VMS is physical activity (20), but  
117 as the evidence is ambiguous it is not included in prevailing VMS treatment guidelines.

118 Women with VMS appear to have an unfavorable cardiovascular risk profile and previous  
119 observational studies have found associations with cardiovascular risk factors such as  
120 hypertension, hypercholesterolemia, and overweight/obesity (21). Studies on measures of  
121 subclinical ASCVD have yielded discrepant results. Associations with carotid intima media  
122 thickness (C-IMT) and aortic calcification have been demonstrated (21-24) but not with  
123 coronary artery calcium (CAC) (21). In prospective studies, associations between VMS and  
124 major adverse cardiac events (MACE) have been observed (25, 26). However, no distinct

125 mechanism has yet been identified and it is still unclear whether VMS constitutes an  
126 independent risk factor for developing ASCVD.

127 To gain a better understanding of how VMS are associated with ASCVD, population-based  
128 studies are needed, allowing for comprehensive adjustments. Using subclinical outcome  
129 measures has the advantage of investigating associations with early-stage ASCVD when the  
130 opportunities for preventive interventions are greatest. Previous research addressing a  
131 possible association between VMS and subclinical ASCVD has been limited to the use of  
132 CAC and carotid ultrasound measurements as outcomes. The current study adds coronary  
133 computed tomography angiography (CCTA), a low dose imaging technique measuring  
134 coronary atherosclerosis with the ability to identify both the anatomical distribution and the  
135 characteristics of coronary atherosclerosis and plaques (27).

136 The current study aimed to assess associations between VMS and subclinical ASCVD  
137 detected through CCTA, CACS or carotid ultrasound, and to determine if potentially observed  
138 associations are modified by cardiovascular related risk factors.

## 139 2. Material & Methods

### 140 2.1. Study design and population

141 This is a sub-study of the Swedish CARDioPulmonary BioImage Study (SCAPIS) - a  
142 multicenter population-based observational study aimed at improving prediction and  
143 prevention of CVD (26). The SCAPIS protocol, described in detail elsewhere (26), was  
144 consistent for all centers and included collection of data through a comprehensive  
145 questionnaire, anthropometry, electrocardiogram (ECG), blood pressure, accelerometer  
146 measurements of physical activity, blood sampling, and extensive cardiovascular imaging.

147 Female study participants at two of the SCAPIS centers (Stockholm and Linköping) were  
148 invited to participate in the sub-study Survey on Women's Health (SWH), requiring  
149 completion of an additional questionnaire including questions about menopausal status, age at  
150 menstrual cessation, menopausal symptoms including VMS, and the use of MHT and  
151 naturally derived compounds. The questionnaire was first tested in a small pilot study and  
152 some adjustments for greater clarity were made. Of the women invited to the SWH, 98% (n =  
153 5043) agreed to participate. Among those, 578 women gave no information about menopausal  
154 status and were therefore not considered. The current study also has the following exclusion  
155 criteria: 1) being premenopausal (i.e., regular menses during the last year), 2) loss of



156 menstruation due to other causes than natural menopause (hormonal treatments, surgical  
157 menopause, excessive exercising or dietary restrictions, pregnancy or breastfeeding), and 3)  
158 missing data on VMS.

159 The data collection took place between October 2015 and March 2018 in Stockholm and  
160 between October 2015 and June 2018 in Linköping. Data from SCAPIS were linked through  
161 each individual's unique personal identification number to the National Patient Register and  
162 the National Prescribed Drug Register, maintained by the National Board of Health and  
163 Welfare, in order to obtain information about medical history.

## 164 2.2. Menopause and vasomotor symptoms

165 Menopausal status was defined as perimenopausal (<12 months amenorrhea), early  
166 postmenopausal ( $\geq$ 12-36 months amenorrhea), late postmenopausal (>36-72 months  
167 amenorrhea) or very late postmenopausal (>72 months amenorrhea).

168  
169 The SWH asked whether the women had ongoing or previous VMS, and if so to what degree  
170 and with what duration. Information on age at the start of VMS was requested. In case of  
171 MHT, the instruction was to report VMS as they were before medication initiation. A four-  
172 point intensity scale was used, in accordance with the structure of "The Greene climacteric  
173 scale" (28), an established questionnaire to identify VMS: 1) never, 2) mild, 3) moderate, or  
174 4) severe VMS. Herein, ongoing or previous exposure to VMS, regardless of intensity, are  
175 collectively referred to as 'never', 'mild', 'moderate' or 'severe' VMS. The questionnaire  
176 included a question on frequency of VMS in the last two weeks, with five predefined response  
177 options: 1) no symptoms, 2) occasionally, 3) a few times per week, 4) once a day, and 5)  
178 several times per day. Women also reported on whether they had other menopausal symptoms  
179 or ever used naturally derived herbal medicine as treatment (e.g., phytoestrogens) for VMS.

## 180 2.3. Coronary and carotid atherosclerosis measures

181 CCTA data were collected using multi-slice CT scanner (Siemens, Somatom Definition Flash,  
182 Siemens Healthineers, Erlangen, Germany). Identical software and hardware were used at  
183 both study sites. Details of image collection, processing, analyses, reconstruction, reading,  
184 and scoring are published elsewhere (29). Atherosclerosis was reported in 18 segments (30),  
185 with findings from the most clinically relevant segments (1 through 3, 5 through 7, 9, 11  
186 through 13, and 17) mandatory to report. Coronary artery status was classified as no  
187 atherosclerosis, any atherosclerosis, nonsignificant (i.e., 1% to 49%) stenosis, significant (i.e.,

188  $\geq 50\%$ ) stenosis, missing segment or not assessable due to calcium blooming or technical  
189 failure. The coronary segmental involvement score (SIS) was calculated by adding the  
190 segments with present atherosclerosis and a score  $>3$  indicates more widespread  
191 atherosclerosis.

192 The CAC images were acquired using ECG-gated non-contrast CT at 120 kV and CAC score  
193 (CACS) was calculated after summing the calcium content in each coronary artery according  
194 to Agaston (31). In regression analyses, CACS was dichotomized into 0-100 or  $>100$  Agaston  
195 units.

196 The carotid arteries were assessed bilaterally for atherosclerotic plaques in the common  
197 carotid artery, bulb, and the internal carotid artery. Results were categorized as no, unilateral,  
198 or bilateral plaques. Siemens Acuson S2000 ultrasound scanner equipped with a 9L4 linear  
199 transducer (Siemens Healthineers, Erlangen, Germany) was used according to a standardized  
200 protocol. The definition of plaques is described in more detail elsewhere (32, 33).

201 The primary measures of subclinical ASCVD in the present study were 1) any coronary  
202 atherosclerosis, 2) SIS  $>3$ , 3) CACS  $>100$ , and 4) any carotid plaque.

#### 203 2.4. Covariates

204 The procedures behind the physical examinations, anthropometry and the collection and  
205 analyzing of blood samples have previously been described (29). Based on questionnaire data,  
206 binary variables for educational level, country of birth, employment status, financial strain,  
207 quality of sleep, continuous stress, depressive symptoms, and specific medical diagnoses were  
208 created. Details about how all variables were created are given in supplement. The  
209 participants were categorized as current, previous, or never smokers. Among smokers, the  
210 sum of cigarette pack-years was calculated. Data on family history of myocardial infarction  
211 (MI) and stroke, respectively, and alcohol habits were obtained from the questionnaire and  
212 treated as binary variables (see supplement).

213 Accelerometry was used to measure physical activity and sedentary time. Study participants  
214 wore a tri-axial accelerometer (ActiGraph LCC, Pensacola) on their right hip during waking  
215 hours for seven consecutive days. The ActiLife v.6.13.3 software was used to set up,  
216 download and process the data (34). The processed data were registered as counts per minute  
217 (cpm), with higher cpm indicating more intense physical activity. Physical activity intensities  
218 were categorized into 1); "Sedentary"; 0 and 199 cpm 2) "Light physical activity"; 200-2689  
219 cpm and 3) 'Moderate to vigorous (MVPA)';  $\geq 2690$  cpm, based on percentage of all wear

220 time, in accordance with previous studies (34). The variables, MVPA and sedentary, were  
221 used descriptively for this study and MVPA was used in the regression models.

222 Women who reported use or past use of systemic prescription MHT, either in the form of oral  
223 pills, transdermal patches or transdermal gels and irrespective of indication, were considered  
224 as ever users of MHT. Subsequently, a categorical variable was created considering duration  
225 of use: 1) never user, 2) 1-4 years, and 3)  $\geq 5$  years. For sensitivity analyses, a subcategory of  
226 women who initiated MHT  $>6$  years since menopause was created.

## 227 2.5. Statistical analysis

228 Mean and standard deviation (SD) or median with 25<sup>th</sup> and 75<sup>th</sup> percentiles were calculated  
229 for continuous variables as appropriate, depending on data being normally distributed or not.  
230 Data distribution also determined whether independent T-tests or Mann-Whitney U tests were  
231 used to assess statistical significance in comparisons across groups; the Chi<sup>2</sup> test was used for  
232 categorical variables. Multivariate logistic regression models were performed to assess  
233 associations between VMS and subclinical ASCVD, with results presented as odds ratios  
234 (OR) with 95 % confidence intervals (CI). Women who never had experienced VMS and  
235 women with mild VMS were combined (herein referred to as the never/mild group) and  
236 served as the reference category in all analyses, in comparison with the moderate and severe  
237 groups, respectively. Women with a history of ischemic heart disease (definition given in  
238 supplement), percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting  
239 (CABG) were excluded in analyses of associations between VMS and coronary  
240 atherosclerosis and CACS, and women with a history of ischemic stroke were excluded when  
241 analyzing associations with carotid plaques (Figure 1). Crude univariate models, and five  
242 multivariate models adjusted for different sets of variables were used. Model 1 included age  
243 at time of study inclusion and site. Model 2 included model 1 and a block of socioeconomic,  
244 demographic, lifestyle related and clinical cardiovascular risk factors: educational level,  
245 country of birth, menopausal status, systolic blood pressure, waist circumference, low density  
246 lipoprotein (LDL) cholesterol, triglycerides, diabetes mellitus, medically treated  
247 hyperlipidemia, medically treated hypertension, and smoking status. Model 3 included model  
248 2 and a block of additional factors previously shown to be more prevalent among women with  
249 VMS and suggested to associate with ASCVD: continuous stress, quality of sleep, depression,  
250 and sleep apnea. Model 4 and Model 5 included model 3 and in addition MVPA and MHT,  
251 respectively, to explore any change in OR point estimates.

252 To investigate whether duration of VMS had a bearing on the studied associations between  
253 VMS and subclinical ASCVD, we created a binary variable distinguishing longer and shorter  
254 duration. Since there is no established limit to make such distinction, we chose a cut-off  
255 corresponding to the median VMS duration in in the study sample. Then a variable was  
256 created with the following categories: 1) never/mild (reference), 2) moderate VMS  $\leq 5$  years,  
257 3) moderate VMS  $> 5$  years, 4) severe VMS  $\leq 5$  years, and 5) severe VMS  $> 5$  years.  
258 Correspondingly, we investigated whether the timing of the start of the VMS had a bearing on  
259 the studied association between VMS and ASCVD. The variable created had the following  
260 categories: 1) never/mild VMS (reference), 2) moderate VMS starting before menopause, 3)  
261 moderate VMS starting after menopause, 4) severe VMS starting before menopause, and 5)  
262 severe VMS starting after menopause.

263 In supplementary analyses of VMS intensity in relation to coronary atherosclerosis, women  
264 with mild VMS served as the reference category, whereas women who had never experienced  
265 VMS constituted a separate category. Supplementary analyses were also performed to assess  
266 VMS in relation to CACS  $> 0$  as well as bilateral and unilateral carotid plaques. Finally, a  
267 sensitivity analysis was performed excluding women with late start ( $> 6$  years) of MHT. Self-  
268 reported physical activity was also considered instead of the objectively measured MVPA in a  
269 separate sensitivity analysis.

270 P-values  $< 0.05$  were considered to indicate statistical significance. All analyses were  
271 performed with SPSS v.28.0 (IBM, Portsmouth, UK).

### 272 3. Ethical considerations

273 This study was conducted in accordance with the Declaration of Helsinki, with oral and  
274 written informed consent before participation. The SCAPIS study as well as the SWH was  
275 approved by the Swedish Ethical Review Authority (reference numbers: 2010-228-31M,  
276 2015-246/32, and 2020-03101). SN and KL had full access to all the data in the study and  
277 take responsibility for its integrity and the data analysis. The authors declare that all  
278 supporting data are available within the article.

## 279 4. Results

### 280 4.1 Descriptive characteristics

281 Among the randomly selected Swedish men and women invited to participate in SCAPIS,  
282 30,154 individuals were recruited (50.3%). The participation rate was similar between sexes

283 and ages (27). The mean age of the 4465 participants in the SWH population was 57.4 years;  
284 82.6% were postmenopausal and 8.2% perimenopausal (characteristics presented in  
285 Supplementary Tables 1-3). After excluding participants according to the pre-specified  
286 criteria, 2995 women remained and constituted the study population (Figure 1). Of these,  
287 43.3% reported mild, 18.1% moderate, and 14.2% severe VMS whereas 24.4% had never  
288 experienced VMS. Women in the severe group were more likely to be postmenopausal (93.4  
289 vs 88.9%,  $p < 0.01$ ), and they experienced other menopausal symptoms (42.1 vs 24.3%,  
290  $p < 0.01$ ) and used herbal medicines (e.g., phytoestrogens) (20.4 vs 5.5%,  $p < 0.01$ ) to a greater  
291 extent than women with never/mild VMS. Characteristics of the study population by VMS  
292 intensity are presented in Tables 1 and 2.

293 VMS occurred significantly earlier in women who reported ever severe VMS, than in those  
294 who reported never/mild VMS (mean age 49.4 vs 50.5,  $p < 0.01$ ). The duration of VMS was  
295 significantly longer in both the severe VMS group (median 6 years) and the moderate VMS  
296 group (median 5 years) than in the never/mild group (median 4 years;  $p < 0.01$ ). There was a  
297 significantly higher frequency of daily VMS the past two weeks in the severe (68.6%) and  
298 moderate (62.3%) group than in the never/mild group (29.1%) (Table 2).

299 Among women in the study population with current or previous MHT use, 91.6% started their  
300 treatment within 6 years after menopause and the median duration of use was 4 years. Women  
301 with ever severe or moderate VMS were more likely to have used MHT compared to the  
302 never/mild group (50.3 vs 10.9% and 31.7 vs. 10.9%;  $p < 0.01$ ). In women with severe VMS,  
303 24.9% had used MHT for  $\geq 5$  years, while the corresponding proportions in the moderate and  
304 mild VMS group were 12.2% and 3.5% (Table 2).

305 Women in the severe VMS group were more often born outside Sweden, had lower education,  
306 and suffered from financial strain the last year more than the never/mild VMS group. Further,  
307 they reported worse sleep habits and more continuous stress the last 5 years, were more often  
308 overweight, sedentary, past smokers and had smoked more pack years of cigarettes.

309 Approximately 30% in this group fulfilled criteria for depression compared to 20% in the  
310 never/mild VMS group. There were no differences between VMS groups in MVPA, blood  
311 pressure or cardiometabolic biomarkers, except triglycerides, which were higher in the severe  
312 VMS group ( $p < 0.01$ )(Table 1).

313 The prevalence of any CCTA-detected coronary atherosclerosis was higher in the severe  
314 VMS group than in the never/mild group (34.1 vs. 27.8%,  $p = 0.017$ ). Similarly, CACS  $> 0$

315 was more prevalent in the severe VMS group than in the never/mild group (34.4 vs 29.3%, p  
316 = 0.014). For moderate VMS there were no corresponding differences compared to the  
317 never/mild group. The prevalence of SIS >3 and CACS >100 did not differ significantly  
318 between groups. The prevalence of bilateral carotid plaques was higher in the severe group  
319 compared to the never/mild group (21.9 vs 17.5%, p = 0.032), but for the moderate group the  
320 corresponding difference was not observed (19.1 vs. 17.5%, p = 0.398). The prevalence of  
321 unilateral carotid plaques did not differ significantly between groups (Table 3).

322 In supplemental analyses, the group who never had any VMS was compared to the group  
323 reporting mild VMS (Supplementary Tables 5-7). Women who never experienced VMS were  
324 significantly older, more often born outside Sweden, lower educated, unoccupied, and  
325 suffered from financial strain the last year more often than the group with mild VMS. They  
326 were also more frequently obese, and had on average a greater waist circumference, higher  
327 blood pressure and a worse cardiometabolic biomarker risk profile compared to women with  
328 ever mild VMS. The prevalence of ischemic stroke, hypertension, and diabetes mellitus was  
329 also higher in this group. In addition, they had higher CACS and a more widespread coronary  
330 atherosclerosis than women with mild VMS.

331 The proportion of missing data was <8% for the variables used in the regression models. The  
332 frequency of missing data for all variables is given in the Supplementary Table 4.

#### 333 4.2 VMS in relation to subclinical ASCVD

334 The results from the multivariable regression models with subclinical ASCVD are presented  
335 in Supplementary Table 8 and illustrated in Figure 2. Severe VMS were significantly  
336 associated with coronary atherosclerosis (crude OR 1.36, 95% CI 1.08 – 1.72). The  
337 association was slightly weaker after the multivariable adjustment in model 3, OR 1.33 (95%  
338 CI 1.02-1.72) whereas additional adjustment for MHT (model 5) yielded a slightly stronger  
339 association, OR 1.41 (95% CI 1.06-1.87). In model 5, when excluding women with start of  
340 MHT > 6 years after menopause, the result remained similar (OR 1.44, 95% CI 1.08 – 1.93)  
341 (Supplementary Table 9). Moderate VMS was not significantly associated with coronary  
342 atherosclerosis in any of the models.

343 If severe VMS lasted >5 years, the association with coronary atherosclerosis was more  
344 pronounced, crude OR 1.70, 95% CI 1.26 – 2.30 (Figure 2 and Supplementary Table 10). This  
345 association was weakened but still significant in model 1, (OR 1.48, 95% CI 1.09 – 2.01), and  
346 similar in model 2 (OR 1.49, 95% CI 1.07 – 1.97), model 3, (OR 1.53, 95% CI 1.09 – 2.14)



347 and model 4 (OR 1.50, 95% CI 1.07 – 2.11). In model 5, where MHT was added, the  
348 association was strengthened (OR 1.67, 95% CI 1.16 – 2.40) (Figure 2). For severe VMS with  
349 shorter duration ( $\leq 5$  years), the association with coronary atherosclerosis was not significant  
350 (Supplementary Table 10). For moderate VMS, no effect of symptom duration was observed  
351 in relation to coronary atherosclerosis (Supplementary Table 10). For severe VMS that started  
352 before menopause, but not for VMS that started after menopause, a significant association  
353 with coronary atherosclerosis was observed that persisted after multivariable adjustments,  
354 model 3 OR 1.60 (95% CI 1.06-2.42) and model 5 OR 1.69 (95% CI 1.10 - 2.60)  
355 (Supplementary Table 11).

356 Neither moderate nor severe VMS were significantly associated with CACS  $>100$ ,  
357 widespread coronary disease (SIS  $>3$ ) or any carotid plaque (Supplementary Table 8, Figure  
358 2). In supplementary analyses, severe VMS were significantly associated with CACS  $>0$  in  
359 the crude model but not after multivariable adjustments (Supplementary Table 12). Severe  
360 VMS were significantly associated with bilateral carotid plaques in crude analyses and  
361 borderline significant after multivariable adjustments (Supplementary Table 13). For  
362 unilateral plaque, no significant association was observed.

## 363 5. Discussion

364 In this nation-wide population-based study, we found that ongoing or previous severe, but not  
365 moderate, VMS were significantly associated with coronary atherosclerosis detected with  
366 CCTA, independent of a wide range of lifestyle, socioeconomic and clinical cardiovascular  
367 risk factors. To our knowledge this is the first time CCTA data have been used assessing the  
368 association between VMS and subclinical ASCVD.

369 In keeping with a previous study (13), women who experienced severe VMS had the earliest  
370 onset and longest duration of VMS. Arguably, VMS duration could have bearing on the  
371 strength of the association to coronary atherosclerosis. To the best of our knowledge, this has  
372 not been studied previously, and interestingly, our results show that severe VMS lasting  $>5$   
373 years were significantly associated with coronary atherosclerosis, whereas no corresponding  
374 association was observed for shorter durations. Moderate VMS, however, was not associated  
375 with coronary atherosclerosis regardless duration. We also found that pre-menopausal but not  
376 post-menopausal onset of severe VMS was associated with coronary atherosclerosis. These  
377 findings agree with the American Study of Women's Health Across the Nation, which  
378 reported associations between frequent VMS persistence over time and incident CVD (25).

379 The findings are also consistent with results from the Women's Ischemia Syndrome  
380 Evaluation (WISE) that show associations between early onset VMS and reduced endothelial  
381 function and CVD mortality (35). However, results from a study that pooled data from six  
382 different prospective studies show that both pre-menopausal and post-menopausal onset of  
383 VMS are associated with incident CVD (26).

384 The persisting association between severe VMS and coronary atherosclerosis after adjustment  
385 for conditions known to be prevalent in women with VMS, such as sleep disturbances and  
386 depression (13, 14), is on the one hand surprising as VMS could have a negative impact on  
387 lifestyle and sleep quality, which in turn could increase the risk of ASCVD. On the other  
388 hand, our results are consistent with several previous studies of VMS in relation to subclinical  
389 CVD and incident manifest CVD where no substantial impact on the results were observed  
390 when adjusting for such covariates (22-26). Although it cannot be ruled out that severe VMS  
391 is merely a marker of an unfavorable cardiovascular risk profile, our findings of an  
392 independent relationship between severe VMS and coronary atherosclerosis could indicate an  
393 unknown underlying pathophysiological mechanism, either in the initiation or the progression  
394 of the atherosclerotic process in midlife women. Further research is required to elucidate  
395 mechanisms by which VMS may exert a deleterious effect on the coronary arteries, but we  
396 can speculate that women with long-term severe VMS or whose severe VMS started early  
397 may have increased sensitivity to hormonal fluctuations, which in turn may contribute to  
398 atherosclerotic development via autonomic neurovascular dysregulation (36). Thus, these  
399 women may in general have an underlying adverse vascular reactivity manifested during the  
400 menopausal transition. Effects could perhaps be related to an over-reactivity of the  
401 sympathetic nervous system, with inhibition of cardiac vagal control (37), or to changes in the  
402 hypothalamic-pituitary-adrenal (HPA) axis associated with variable cortisol concentrations  
403 (38, 39). Furthermore, because the fast withdrawal of estrogen during menopausal transition  
404 rather than the absolute plasma level may be connected to an instability in the  
405 thermoregulatory center in hypothalamus (40), it seems reasonable that increased central  
406 thermoregulatory sensitivity or hampered adaptation capacity may indirectly be related to a  
407 heightened central sympathetic tone, resulting in an over-activity of the sympathetic nervous  
408 system (40, 41).

409 The analyses of VMS in relation to the other subclinical ASCVD measurements - CACS  
410 >100, SIS >3 and any carotid plaque - showed no significant associations. To improve  
411 comparison to previous study results, we added analyses on VMS in relation to CACS >0.



412 Still, we observed no significant associations after multiple adjustments (Supplementary  
413 Table 12). These findings are in line with most previous studies on VMS in relation to CACS  
414 and/or carotid atherosclerosis(21), with some exceptions (22, 23). CCTA is a diagnostical and  
415 non-invasive angiographic method able to detect coronary artery disease (CAD), compared to  
416 CAC that rather predicts risk for future manifest CVD events (42). While CACS reflects the  
417 sum of coronary calcifications, CCTA can detect calcified as well as non-calcified plaques,  
418 degree of plaque stenosis, and extended plaque features such as plaque stability and  
419 anatomical distribution (43). Thus, VMS might be associated to early coronary  
420 atherosclerosis, already before the development of calcified plaques, which might explain the  
421 observation of a strong and independent association for CCTA-detected coronary  
422 atherosclerosis but not with coronary calcification. Since SIS >3 was uncommon in the  
423 included age group, we might lack statistical power to detect significant differences and thus  
424 cannot rule out true associations. Although the atherogenesis appears to be similar for both  
425 coronary and carotid plaques (44), the lack of significant associations between severe VMS  
426 and any carotid plaque could relate to a different pathophysiology behind the development of  
427 coronary and carotid atherosclerosis. However, in the supplementary analyses severe VMS  
428 were borderline significantly associated with bilateral carotid plaque, which compared to  
429 unilateral carotid disease has been shown so be a better predictor of the 5-year risk of  
430 coronary death (45). Although this may be a spurious finding, there is a possibility that  
431 unilateral carotid atherosclerosis is rather caused by anatomical and hemodynamic factors,  
432 while bilateral carotid plaques reflect a more extensive atherosclerotic disease with systemic  
433 factors giving rise to its development (45).

434 For analyzes of VMS in relation to subclinical ASCVD, the choice of “reference group” is not  
435 obvious and varying definitions of “bothersome” symptoms makes comparisons between  
436 studies challenging. In previous studies, women without VMS have usually constituted the  
437 reference group. We found that women who never experienced VMS had significantly more  
438 cardiovascular risk factors and coronary atherosclerosis than women with mild VMS, a  
439 finding consistent with the results from the WISE study, which observed an increased CVD  
440 mortality in this group compared with women with late-onset VMS (35). Thus, women  
441 without VMS may not always have the lowest risk of developing ASCVD and thus our  
442 reference category also included women who reported mild VMS, which constituted the  
443 largest group in our study population (43.3%) (Supplementary Table 14).

444 Women with severe VMS performed MVPA to a similar extent as women with no or mild  
445 VMS. Neither did self-reported level of physical activity differ significantly between the  
446 groups. Hence, we found no indication that physical activity would mitigate a potential  
447 detrimental effect of VMS on the coronary arteries. This somewhat contradicts previous  
448 results showing that physically active as compared to sedentary postmenopausal women  
449 report less VMS (20). Although the current study was not designed to study treatment effects,  
450 it is relevant to note that the association between >5 years of VMS and coronary  
451 atherosclerosis became stronger when adjusting for MHT, as this could possibly signal a  
452 mitigating effect. However, this result must be interpreted with caution due to bias related to  
453 confounding by indication. Contraindications for prescribing MHT have since the WHI-study  
454 (46) included a history of cardiovascular disease, which means a selection of cardiovascular  
455 healthier women prescribed MHT. On the other hand, VMS severity could also influence  
456 whether the woman is treated with MHT or not, which, under the assumption that severe  
457 VMS affect the development of subclinical atherosclerosis, means a selection against  
458 cardiovascular less healthy women prescribed MHT.

459 There are several limitations to our study. Firstly, the cross-sectional observational study  
460 design limits any causal conclusions to be drawn since we do not know when VMS appeared  
461 in relation to the atherosclerosis development. Secondly, the results may not be generalizable  
462 to other geographical regions, ethnicities and age-groups since the definitions and prevalence  
463 of VMS differ (10, 13). Thirdly, the assessment of VMS may be subject to recall bias, given  
464 that up to 10-15 years could have passed since the study participants experienced their  
465 symptoms. However, it is likely that such recall bias would be non-differential because the  
466 women were not aware of their measures of subclinical coronary atherosclerosis or other  
467 cardiovascular risk assessments when they completed the questionnaire. In that case, this  
468 would have a weakening effect on our results.

## 469 6. Conclusions

470 Ongoing or previous severe VMS, with >5 years duration or beginning before menopause,  
471 were significantly associated with subclinical CCTA-detected coronary atherosclerosis,  
472 independent of a wide range of socioeconomic, demographic, lifestyle-related and clinical  
473 cardiovascular risk factors. No corresponding associations were observed for SIS >3, CACS  
474 >100 or any carotid plaque. Further research is required to establish a possible causal  
475 relationship between severe VMS and coronary atherosclerosis, as well as the

476 pathophysiological mechanism behind such association. However, our findings support a  
477 more consistent implementation of preventive cardiovascular strategies in gynecological care,  
478 targeting women with severe VMS which may be a marker of poor or ongoing deterioration  
479 of cardiovascular health. Here is a window of opportunity for preventing cardiovascular  
480 disease in midlife women, as severe VMS increase the propensity to seek medical advice.

## 481 7. Acknowledgements

482 We would like to thank Professor and MD Mats Hammar for his support in conceptualization  
483 of the SWH questionnaire. In addition, authors would like to thank Max Vikström  
484 (Karolinska Institutet, Unit of Cardiovascular and Nutritional Epidemiology, Institute of  
485 Environmental Medicine, Stockholm, Sweden) for his assistance and support with the  
486 statistical analyses.

487

## 488 Funding

489 The main funding body of The Swedish CARDioPulmonary bioImage Study (SCAPIS) is the  
490 Swedish Heart-Lung Foundation. The study is also funded by the Knut and Alice Wallenberg  
491 Foundation, the Swedish Research Council and VINNOVA (Sweden's Innovation agency)  
492 the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and  
493 Stockholm County council, Linköping University and University Hospital, Lund University  
494 and Skåne University Hospital, Umeå University and University Hospital, Uppsala University  
495 and University Hospital. The current study was supported by grants from the Swedish Heart-  
496 Lung foundation (grant number 20220190) to KL and grants from the County Council of  
497 Östergötland to ACSH.

## 498 Disclosures

499 There are no financial conflicts of interest to disclose.

## 500 Author contributions

501 Sigrid Nilsson contributed to investigation, validation, visualisation, methodology, formal  
502 analysis, writing the original draft, reviewing, and editing the manuscript.

503 Angelika Qvick contributed to investigation, validation, visualisation, methodology, writing  
504 the original draft, reviewing, and editing the manuscript.

505 Moa Henriksson contributed to data curation, reviewing, and editing the manuscript.

506 Anna-Clara Spetz Holm contributed to supervision, conceptualisation, project administration,  
507 validation, investigation, reviewing and editing the manuscript.

508 Sofia Sederholm Lawesson contributed to supervision, validation, investigation,  
509 methodology, reviewing and editing the manuscript.

510 Karin Leander contributed to supervision, conceptualisation, project administration, data  
511 curation, methodology, validation, investigation, reviewing and editing the manuscript, and  
512 funding acquisition.

## 513 ORCID-ID

514 SN: [sigrid.nilsson@liu.se](mailto:sigrid.nilsson@liu.se), 0000-0002-9604-8062

515 AQ: [angelika.qvick@ki.se](mailto:angelika.qvick@ki.se), 0000-0003-4149-5399

516 MH: [moa.a.henriksson@liu.se](mailto:moa.a.henriksson@liu.se), 0000-0003-2592-1140

517 ACSH: [anna-clara.spetz.holm@liu.se](mailto:anna-clara.spetz.holm@liu.se), 0000-0002-0268-2901

518 SSL: [sofia.lawesson@liu.se](mailto:sofia.lawesson@liu.se), 0000-0002-4776-0870

519 KL: [Karin.Leander@ki.se](mailto:Karin.Leander@ki.se), 0000-0002-1404-9222

## 520 Supplemental Material

521 Supplemental methods

522 Supplemental tables 1-14

523 References (47-50)

## 524 Figure legends

525 Figure 1. Flowchart for selection of the study population (n=2995)

526 SCAPIS = Swedish CArdioPulmonary bioImage Study; ASCVD = Atherosclerotic  
527 cardiovascular disease; SWH = Study of Women's health; VMS = Vasomotor symptoms;  
528 CCTA = Coronary computed tomography angiography; CAC = Coronary artery calcium; IHD  
529 = Ischemic heart disease; PCI = Percutaneous coronary intervention; CABG = Coronary  
530 artery bypass graft. \* Hormonal treatments, surgical menopause, excessive exercising or  
531 dietary restrictions, pregnancy or breastfeeding.

532 Figure 2. Vasomotor intensity and duration in relation to occurrence of subclinical  
533 ASCVD.

534 The panels show results different subclinical ASCVD measures: Panel a) Any coronary  
535 atherosclerosis, Panel b) SIS >3, Panel c) CACS >100, and Panel d) any carotid plaque. All  
536 statistical comparisons have the never/mild group as reference. CRUDE: no adjustments;  
537 Model 1: age at time of study inclusion + site; Model 2: model 1 + highest degree of  
538 education, country of birth, systolic blood pressure, waist circumference, low density  
539 lipoprotein, triglycerides, diabetes mellitus, hyperlipidemia, hypertension, smoking status,  
540 and menopausal status; Model 3: model 2 + experienced stress, sleep habits, depression,  
541 and sleep apnea; Model 4: model 3 + moderate to vigorous physical activity; Model 5: model  
542 3 + menopausal hormone therapy. SCAPIS = Swedish CArdioPulmonary bioImage Study;  
543 VMS = Vasomotor symptoms. SCAPIS = Swedish CArdioPulmonary bioImage Study;  
544 ASCVD = Atherosclerotic cardiovascular disease; VMS = Vasomotor symptoms; Segmental  
545 involvement score; CACS = Coronary artery calcium score.

546

## 547 References

- 548 1. Wenger NK, Lloyd-Jones DM, Elkind MSV, Fonarow GC, Warner JJ, Alger HM,  
549 et al. Call to Action for Cardiovascular Disease in Women: Epidemiology, Awareness,  
550 Access, and Delivery of Equitable Health Care: A Presidential Advisory From the American  
551 Heart Association. *Circulation*. 2022;145(23):e1059-e71.
- 552 2. Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, et al.  
553 Cardiovascular health after menopause transition, pregnancy disorders, and other  
554 gynaecologic conditions: a consensus document from European cardiologists,  
555 gynaecologists, and endocrinologists. *Eur Heart J*. 2021;42(10):967-84.
- 556 3. Sederholm Lawesson S, Swahn E, Pihlsgard M, Andersson T, Angeras O,  
557 Bacsovcics Brodin E, et al. Association Between History of Adverse Pregnancy Outcomes and  
558 Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography.  
559 *JAMA*. 2023;329(5):393-404.
- 560 4. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD,  
561 et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of  
562 Early Prevention: A Scientific Statement From the American Heart Association. *Circulation*.  
563 2020;142(25):e506-e32.
- 564 5. Garcia M, Mulvagh SL, Merz CN, Buring JE, Manson JE. Cardiovascular  
565 Disease in Women: Clinical Perspectives. *Circ Res*. 2016;118(8):1273-93.
- 566 6. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF,  
567 Sternfeld B, et al. Are changes in cardiovascular disease risk factors in midlife women due to  
568 chronological aging or to the menopausal transition? *J Am Coll Cardiol*. 2009;54(25):2366-  
569 73.
- 570 7. Nelson HD. Menopause. *Lancet*. 2008;371(9614):760-70.
- 571 8. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al.  
572 Management of cardiovascular risk in the peri-menopausal woman: a consensus statement  
573 of European cardiologists and gynaecologists. *Eur Heart J*. 2007;28(16):2028-40.
- 574 9. Gast GC, Grobbee DE, Pop VJ, Keyzer JJ, Wijnands-van Gent CJ, Samsioe  
575 GN, et al. Menopausal complaints are associated with cardiovascular risk factors.  
576 *Hypertension*. 2008;51(6):1492-8.
- 577 10. Yu Q, Chae HD, Hsiao SM, Xie J, Blogg M, Sumarsono B, et al. Prevalence,  
578 severity, and associated factors in women in East Asia with moderate-to-severe vasomotor  
579 symptoms associated with menopause. *Menopause*. 2022;29(5):553-63.
- 580 11. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after  
581 natural menopause: evidence from the Penn Ovarian Aging Study cohort. *Menopause*.  
582 2014;21(9):924-32.
- 583 12. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Granger AL, Fehnel SE, et al.  
584 Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in  
585 the United States. *Climacteric*. 2008;11(1):32-43.
- 586 13. Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold  
587 EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition.  
588 *JAMA Intern Med*. 2015;175(4):531-9.
- 589 14. Tomida M, Otsuka R, Tange C, Nishita Y, Kimura T, Stoelzel M, et al.  
590 Vasomotor symptoms, sleep problems, and depressive symptoms in community-dwelling  
591 Japanese women. *J Obstet Gynaecol Res*. 2021;47(10):3677-90.
- 592 15. Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, et al.  
593 Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?  
594 *Circulation*. 2023;147(7):597-610.
- 595 16. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA,  
596 et al. Impaired endothelial function in young women with premature ovarian failure:  
597 normalization with hormone therapy. *J Clin Endocrinol Metab*. 2004;89(8):3907-13.
- 598 17. Pinna C, Cignarella A, Sanvito P, Pelosi V, Bolego C. Prolonged ovarian  
599 hormone deprivation impairs the protective vascular actions of estrogen receptor alpha  
600 agonists. *Hypertension*. 2008;51(4):1210-7.



- 601 18. Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J,  
602 et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. *N Engl*  
603 *J Med.* 2016;374(13):1221-31.
- 604 19. Nappi RE. The 2022 hormone therapy position statement of The North  
605 American Menopause Society: no news is good news. *Lancet Diabetes Endocrinol.*  
606 2022;10(12):832-4.
- 607 20. Liu T, Chen S, Mielke GI, McCarthy AL, Bailey TG. Effects of exercise on  
608 vasomotor symptoms in menopausal women: a systematic review and meta-analysis.  
609 *Climacteric.* 2022;25(6):552-61.
- 610 21. Franco OH, Muka T, Colpani V, Kunutsor S, Chowdhury S, Chowdhury R, et al.  
611 Vasomotor symptoms in women and cardiovascular risk markers: Systematic review and  
612 meta-analysis. *Maturitas.* 2015;81(3):353-61.
- 613 22. Ryu KJ, Park H, Park JS, Lee YW, Kim SY, Kim H, et al. Vasomotor symptoms  
614 and carotid artery intima-media thickness among Korean midlife women. *Maturitas.*  
615 2022;159:1-6.
- 616 23. Thurston RC, Chang Y, Barinas-Mitchell E, Jennings JR, Landsittel DP,  
617 Santoro N, et al. Menopausal Hot Flashes and Carotid Intima Media Thickness Among  
618 Midlife Women. *Stroke.* 2016;47(12):2910-5.
- 619 24. Thurston RC, Kuller LH, Edmundowicz D, Matthews KA. History of hot flashes  
620 and aortic calcification among postmenopausal women. *Menopause.* 2010;17(2):256-61.
- 621 25. Thurston RC, Aslanidou Vlachos HE, Derby CA, Jackson EA, Brooks MM,  
622 Matthews KA, et al. Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular  
623 Disease Events in SWAN. *J Am Heart Assoc.* 2021;10(3):e017416.
- 624 26. Zhu D, Chung HF, Dobson AJ, Pandeya N, Anderson DJ, Kuh D, et al.  
625 Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of  
626 six prospective studies. *Am J Obstet Gynecol.* 2020;223(6):898 e1- e16.
- 627 27. Bergstrom G, Persson M, Adiels M, Bjornson E, Bonander C, Ahlstrom H, et al.  
628 Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population.  
629 *Circulation.* 2021;144(12):916-29.
- 630 28. Greene JG. A factor analytic study of climacteric symptoms. *J Psychosom Res.*  
631 1976;20(5):425-30.
- 632 29. Bergstrom G, Berglund G, Blomberg A, Brandberg J, Engstrom G, Engvall J, et  
633 al. The Swedish CARDIOpulmonary BIolmage Study: objectives and design. *J Intern Med.*  
634 2015;278(6):645-59.
- 635 30. Budoff MJ, Cohen MC, Garcia MJ, Hodgson JM, Hundley WG, Lima JA, et al.  
636 ACCF/AHA clinical competence statement on cardiac imaging with computed tomography  
637 and magnetic resonance: a report of the American College of Cardiology  
638 Foundation/American Heart Association/American College of Physicians Task Force on  
639 Clinical Competence and Training. *J Am Coll Cardiol.* 2005;46(2):383-402.
- 640 31. Ohnesorge B, Flohr T, Fischbach R, Kopp AF, Knez A, Schroder S, et al.  
641 Reproducibility of coronary calcium quantification in repeat examinations with retrospectively  
642 ECG-gated multisection spiral CT. *Eur Radiol.* 2002;12(6):1532-40.
- 643 32. Prael U, Holdfeldt P, Bergstrom G, Fagerberg B, Hulthe J, Gustavsson T.  
644 Percentage white: a new feature for ultrasound classification of plaque echogenicity in  
645 carotid artery atherosclerosis. *Ultrasound Med Biol.* 2010;36(2):218-26.
- 646 33. Ostling G, Persson M, Hedblad B, Goncalves I. Comparison of grey scale  
647 median (GSM) measurement in ultrasound images of human carotid plaques using two  
648 different softwares. *Clin Physiol Funct Imaging.* 2013;33(6):431-5.
- 649 34. Ekblom O, Ekblom-Bak E, Bolam KA, Ekblom B, Schmidt C, Soderberg S, et al.  
650 Concurrent and predictive validity of physical activity measurement items commonly used in  
651 clinical settings--data from SCAPIS pilot study. *BMC Public Health.* 2015;15:978.
- 652 35. Thurston RC, Johnson BD, Shufelt CL, Braunstein GD, Berga SL, Stanczyk FZ,  
653 et al. Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia  
654 Syndrome Evaluation (WISE). *Menopause.* 2017;24(2):126-32.

- 655 36. Miller VM, Kling JM, Files JA, Joyner MJ, Kapoor E, Moyer AM, et al. What's in  
656 a name: are menopausal "hot flashes" a symptom of menopause or a manifestation of  
657 neurovascular dysregulation? *Menopause*. 2018;25(6):700-3.
- 658 37. Thurston RC, Matthews KA, Chang Y, Santoro N, Barinas-Mitchell E, von Kanel  
659 R, et al. Changes in heart rate variability during vasomotor symptoms among midlife women.  
660 *Menopause*. 2016;23(5):499-505.
- 661 38. Reed SD, Newton KM, Larson JC, Booth-LaForce C, Woods NF, Landis CA, et  
662 al. Daily salivary cortisol patterns in midlife women with hot flashes. *Clin Endocrinol (Oxf)*.  
663 2016;84(5):672-9.
- 664 39. Sauer T, Tottenham LS, Ethier A, Gordon JL. Perimenopausal vasomotor  
665 symptoms and the cortisol awakening response. *Menopause*. 2020;27(11):1322-7.
- 666 40. Kronenberg F. Menopausal hot flashes: a review of physiology and  
667 biosociocultural perspective on methods of assessment. *J Nutr*. 2010;140(7):1380S-5S.
- 668 41. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology,  
669 treatment. *J Steroid Biochem Mol Biol*. 2014;142:115-20.
- 670 42. Mehta A, Pandey A, Ayers CR, Khera A, Sperling LS, Szklo MS, et al.  
671 Predictive Value of Coronary Artery Calcium Score Categories for Coronary Events Versus  
672 Strokes: Impact of Sex and Race: MESA and DHS. *Circ Cardiovasc Imaging*.  
673 2020;13(8):e010153.
- 674 43. Achenbach S, Raggi P. Imaging of coronary atherosclerosis by computed  
675 tomography. *Eur Heart J*. 2010;31(12):1442-8.
- 676 44. Jashari F, Ibrahim P, Nicoll R, Bajraktari G, Wester P, Henein MY. Coronary  
677 and carotid atherosclerosis: similarities and differences. *Atherosclerosis*. 2013;227(2):193-  
678 200.
- 679 45. Touze E, Varenne O, Calvet D, Mas JL. Coronary risk stratification in patients  
680 with ischemic stroke or transient ischemic stroke attack. *Int J Stroke*. 2007;2(3):177-83.
- 681 46. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick  
682 ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women:  
683 principal results From the Women's Health Initiative randomized controlled trial. *JAMA*.  
684 2002;288(3):321-33.
- 685 47. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al.  
686 Association of psychosocial risk factors with risk of acute myocardial infarction in 11119  
687 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study.  
688 *Lancet*. 2004;364(9438):953-62.
- 689 48. Partinen M, Gislason T. Basic Nordic Sleep Questionnaire (BNSQ): a  
690 quantitated measure of subjective sleep complaints. *J Sleep Res*. 1995;4(S1):150-5.
- 691 49. Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test  
692 (AUDIT): validation of a screening instrument for use in medical settings. *J Stud Alcohol*.  
693 1995;56(4):423-32.
- 694 50. Patten SB, Brandon-Christie J, Devji J, Sedmak B. Performance of the  
695 composite international diagnostic interview short form for major depression in a community  
696 sample. *Chronic Dis Can*. 2000;21(2):68-72.

697

698



699 **Tables**

700 **Table 1. General characteristics by VMS category of the study population,**  
 701 **SCAPIS (n = 2995)**

Characteristics	Never/mild n = 2027 67.7%	Moderate n = 543 18.1%	Severe n = 425 14.2%
<b>Age, mean (SD)<sup>†</sup></b>	58.3 (4.2)	57.7 (4.3) <sup>  </sup>	58.4 (4.1)
<b>Born outside Sweden, n (%)<sup>*</sup></b>	230 (11.5)	53 (9.9)	74 (17.7) <sup>#</sup>
<b>University degree, n (%)<sup>*</sup></b>	1012 (50.7)	285 (53.3)	176 (42.1) <sup>  </sup>
<b>Currently working, n (%)<sup>*</sup></b>	1681 (83.9)	462 (86.4)	345 (82.3)
<b>Financial strain, n (%)<sup>*</sup></b>	62 (3.1)	18 (3.4)	28 (6.7) <sup>#</sup>
<b>Smoking status, n (%)<sup>*</sup></b>			
Past	753 (38.1)	217 (40.9)	197 (48.0) <sup>#</sup>
Current	209 (10.6)	68 (12.8)	55 (13.4)
<b>Pack years for cigarettes, median (25<sup>th</sup> – 75<sup>th</sup> percentile)<sup>‡</sup></b>	10.5 (4.5 – 19.5)	11.8 (5.0 – 21.0)	13.3 (5.5 – 21.0) <sup>§</sup>
<b>Medical history, n (%)<sup>*</sup></b>			
Ischemic heart disease	39 (1.9)	5 (0.9)	4 (0.9)
Ischemic stroke	41 (2.0)	11 (2.0)	6 (1.4)
Hypertension	353 (17.4)	93 (17.1)	80 (18.8)
Hyperlipidemia	166 (8.2)	31 (5.7)	24 (5.6)
Diabetes mellitus	78 (3.8)	14 (2.6)	16 (3.8)
Sleep apnea	45 (2.2)	8 (1.5)	12 (2.8)
<b>Family history, n (%)<sup>*</sup></b>			
Myocardial infarction	144 (7.2)	32 (6.0)	32 (7.7)
Stroke	126 (6.3)	30 (5.6)	40 (9.6) <sup>§</sup>

<b>Overweight (25-29.9 kg/m<sup>2</sup>), n (%)</b> <sup>*</sup>	711 (35.1)	224 (41.3) <sup>  </sup>	181 (42.6) <sup>  </sup>
<b>Obese (≥30 kg/m<sup>2</sup>), n (%)</b> <sup>*</sup>	379 (18.7)	83 (15.3)	79 (18.6)
<b>Waist circumference (cm), mean (SD)</b> <sup>†</sup>	89.0 (12.9)	88.8 (11.7)	89.6 (11.7)
<b>Blood pressure (mmHg), mean (SD)</b> <sup>†</sup>			
Systolic blood pressure <sup>†</sup>	128 (18)	128 (18)	128 (19)
Systolic blood pressure >140, n (%) <sup>*</sup>	490 (24.2)	127 (23.4)	102 (24.0)
Diastolic blood pressure <sup>†</sup>	81 (11)	81 (10)	80 (11)
Diastolic blood pressure >90, n (%) <sup>*</sup>	399 (19.7)	98 (18.0)	78 (18.4)
<b>Cardiometabolic biomarkers</b>			
LDL cholesterol (mmol/L), mean (SD) <sup>†</sup>	3.3 (1.0)	3.3 (0.9)	3.3 (1.0)
Triglycerides (mmol/L), mean (SD) <sup>†</sup>	1.0 (5.3)	1.0 (0.5)	1.1 (0.7) <sup>  </sup>
hsCRP (mg/L), median (25 <sup>th</sup> – 75 <sup>th</sup> percentile) <sup>‡</sup>	0.9 (0.6 – 2.1)	0.9 (0.6 – 1.9)	1.1 (0.6 – 2.2)
HbA1c (mmol/mol) Mean (SD) <sup>†</sup>	36.6 (5.9)	36.3 (3.9)	36.6 (5.7)
<b>Subjective experience of bad or very bad sleep, n (%)</b> <sup>*</sup>	281 (14.2)	106 (20.1) <sup>  </sup>	118 (28.9) <sup>#</sup>
<b>Physical activity, mean (SD)</b> <sup>†</sup>			
Sedentary	51.6 (10.0)	51.4 (9.7)	50.0 (9.7) <sup>  </sup>
Moderate/vigorous activity	6.7 (3.4)	6.8 (3.3)	6.5 (3.6)
<b>High alcohol consumption, n (%)</b> <sup>*</sup>	160 (8.9)	76 (15.4) <sup>#</sup>	45 (12.3)
<b>Continuous stress last 1-5 years, n (%)</b> <sup>*</sup>	463 (23.5)	155 (29.2) <sup>  </sup>	133 (32.6) <sup>#</sup>
<b>Depression, n (%)</b> <sup>*</sup>	405 (20.3)	146 (27.3) <sup>#</sup>	120 (29.2) <sup>#</sup>

702 All statistical comparisons have the never/mild group as reference category. SCAPIS = Swedish  
703 CardioPulmonary bioImage Study; VMS = Vasomotor symptoms; SBP = Systolic blood pressure; DBP = Diastolic  
704 blood pressure; LDL = Low density lipoprotein; hsCRP = high sensitivity C-reactive protein. \* Chi2 test; †  
705 Independent T-test; ‡ Mann-Whitney U test; § p < 0.05; || p < 0.01; # p < 0.001.

706 Table 2. Reproduction-related characteristics by VMS category of the study  
707 population, SCAPIS (n = 2995)

Characteristics	Never/mild n = 2027 67.7%	Moderate n = 543 18.1%	Severe n = 425 14.2%
<b>Menopausal status, n (%)<sup>*</sup></b>			
Perimenopausal	225 (11.1)	54 (9.9)	28 (6.6) <sup>#</sup>
Postmenopausal	1802 (88.9)	489 (90.1)	397 (93.4) <sup>#</sup>
Early postmenopausal (0-3 yrs)	338 (20.4)	114 (25.6) <sup>  </sup>	72 (20.0)
Late postmenopausal (>3-6 yrs)	380 (23.0)	116 (26.0)	84 (23.3)
Very late postmenopausal (>6 yrs)	935 (56.6)	216 (48.4) <sup>#</sup>	204 (56.7)
<b>Age at menopause, mean (SD)<sup>†</sup></b>	50.9 (3.6)	51.1 (3.5)	50.6 (4.1)
<b>VMS, n (%)<sup>*,§</sup></b>			
Ongoing/current	642 (53.8)	296 (57.1)	235 (58.8)
Weekly last two weeks	119 (18.5)	50 (16.8)	21 (8.9) <sup>**</sup>
Daily last two weeks	187 (29.1)	185 (62.3) <sup>**</sup>	162 (68.6) <sup>**</sup>
Previous	551 (46.2)	222 (42.9)	165 (41.3)
Age at start of VMS, mean (SD) <sup>†</sup>	50.5 (6.1)	49.9 (5.6)	49.4 (6.4) <sup>#</sup>
Duration, years, median (25 <sup>th</sup> – 75 <sup>th</sup> percentile) <sup>‡</sup>	4.0 (2.0 – 6.0)	5.0 (3.0 – 8.0) <sup>**</sup>	6.0 (3.0 – 10.0) <sup>**</sup>
<b>Other menopausal symptoms, n (%)<sup>*</sup></b>	488 (24.3)	210 (38.9) <sup>**</sup>	178 (42.1) <sup>**</sup>
<b>MHT<sup>*</sup></b>			
Current, n (%)	98 (4.8)	72 (13.3) <sup>**</sup>	111 (26.1) <sup>**</sup>
Previous, n (%)	124 (6.1)	100 (18.4) <sup>**</sup>	103 (24.2) <sup>**</sup>
Start, age, mean (SD) <sup>†</sup>	51.6 (5.5)	51.4 (4.0)	50.9 (4.6)
Duration, years, median (25 <sup>th</sup> – 75 <sup>th</sup> percentile) <sup>‡</sup>	3.0 (1.0 – 5.0)	3.0 (1.0 – 5.0)	5.0 (2.0 – 7.0) <sup>**</sup>

<b>Ever usage of herbal medicine (e.g., phytoestrogens) for VMS, n (%)</b>	110 (5.5)	85 (16.0)**	85 (20.4)**
<b>Medical obstetric history*</b>			
Preeclampsia	107 (5.3)	25 (4.6)	22 (5.2)
Gestational hypertension	43 (2.1)	11 (2.0)	4 (0.9)
Gestational diabetes	51 (2.5)	10 (1.9)	7 (1.7)

---

708 All statistical comparisons have the never/mild group as reference category. SCAPIS = Swedish  
709 CARDioPulmonary bioImage Study; VMS = Vasomotor symptoms; MHT = Menopausal hormone therapy. \* Chi2  
710 test; † Independent T-test; ‡ Mann-Whitney U test; § Women who never experienced VMS were not considered  
711 when reporting results for the 'Never/mild'-group; || p < 0.05 # p < 0.01 \*\* p < 0.001.

712 Table 3. Prevalence of subclinical ASCVD detected by CT, CCTA or  
713 ultrasound by VMS category of the study population, SCAPIS (n = 2995)

Measures	Never/mild n = 2027 67.7 %	Moderate n = 543 18.1%	Severe n = 425 14.2%
<b>CACS, n (%)<sup>*</sup></b>			
>0	578 (29.3)	137 (25.7)	143 (34.4) <sup>§</sup>
1-10	193 (9.8)	47 (8.8)	51 (12.3)
11-100	250 (12.7)	65 (12.2)	68 (16.3)
101-400	107 (5.4)	20 (3.7)	15 (3.6)
> 400	28 (1.4)	5 (0.9)	9 (2.2)
<b>CACS<sup>†</sup>, median (25<sup>th</sup> – 75<sup>th</sup> percentile)<sup>†</sup></b>	26.0 (6.0 – 92.0)	22 (6.5 – 75.5)	21 (6.0 – 71.0)
<b>CCTA, n (%)<sup>*</sup></b>			
Any form of coronary atherosclerosis	516 (27.8)	130 (25.9)	135 (34.1) <sup>§</sup>
Any coronary stenosis ≥50%	28 (1.5)	4 (0.8)	6 (1.5)
SIS >3 <sup>*</sup>	84 (4.5)	16 (3.2)	20 (5.1)
<b>Any carotid plaque, n (%)<sup>*</sup></b>			
Unilateral plaque	588 (29.1)	152 (28.1)	109 (25.7)
Bilateral plaques	354 (17.5)	103 (19.1)	93 (21.9) <sup>§</sup>

714 All statistical comparisons have the never/mild group as reference. SCAPIS = Swedish  
715 CardioPulmonary bioImage Study; VMS = Vasomotor symptoms; ASCVD = Atherosclerotic  
716 cardiovascular disease; CT = Computed tomography; CCTA = Coronary computed tomography  
717 angiography; CACS = Coronary artery calcium score; SIS = Segment involvement score. <sup>†</sup> Chi2 test  
718 Mann-Whitney U test; <sup>\*</sup> Calculation based on the participants with a CAC score >0; <sup>§</sup> p < 0.05.

719



